PBAC's latest decision on Tafluprost: Recommended with restriction (2012). Considered for for the treatment of ocular hypertension and primary open-angle glaucoma.
PBAC outcome
Recommended with restriction
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2012
Submissions
1
2012 → 2012
Eligible population
patients with open-angle glaucoma or ocular hypertension who had been treated with latanoprost-P for at least 6 months but were experiencing ocular signs or symptoms
Therapy area
Ophthalmology
Line of therapy
Later-line
Evidence base
RCT, Single-arm
Primary endpoint
IOP reduction
Key trials
Trial 74458, TFL01, Trial 74457, Trial 77550, Study 77552
Comparator
latanoprost 0.005% with preservative (latanoprost-P)
Economic model
Cost-minimisation
ICER note
Cost analysis approach used rather than ICER; no QALY-based economic evaluation performed. PBAC did not accept non-inferiority claim, making cost-minimisation analysis the only appropriate approach.